Last updated: August 26, 2026
Berkley and Jensen Mucus Relief is a private-label over-the-counter expectorant positioned around guaifenesin, generally in an extended-release tablet format. Its commercial advantage is low-cost substitution for branded guaifenesin products such as Mucinex. The strongest excipient opportunities are tablet robustness, controlled release, swallowability, stability, and cost reduction rather than new chemical-entity protection.
The product’s exact excipient profile depends on the specific Berkley and Jensen SKU, strength, dosage form, and current contract manufacturer. Public retail listings identify multiple Mucus Relief presentations, so excipient and patent conclusions should be tied to the individual Drug Facts label and NDC.
What is Berkley and Jensen Mucus Relief?
Berkley and Jensen Mucus Relief is a BJ’s Wholesale Club private-label respiratory product. The principal active ingredient in the standard Mucus Relief product is guaifenesin, an FDA-recognized expectorant used to loosen phlegm and thin bronchial secretions.
Typical product configurations include:
| Attribute |
Commercial assessment |
| Brand |
Berkley and Jensen |
| Retailer |
BJ’s Wholesale Club |
| Drug category |
OTC expectorant |
| Likely active ingredient |
Guaifenesin |
| Common strength format |
600 mg or 1,200 mg extended-release tablets, depending on SKU |
| Dosage form |
Extended-release tablet for the standard Mucus Relief presentation |
| Regulatory pathway |
OTC monograph or monograph-aligned product |
| Primary competitor |
Mucinex guaifenesin products |
| Commercial model |
Private-label, value-priced substitution |
| Main technical barrier |
Reproducible extended release and tablet performance |
FDA’s OTC expectorant monograph identifies guaifenesin as an active ingredient for use in products labeled to relieve cough associated with minor throat and bronchial irritation.[1]
What excipients are likely used in Berkley and Jensen Mucus Relief?
The precise inactive-ingredient list must be taken from the current package label or electronic listing for the applicable SKU. Extended-release guaifenesin tablets commonly use excipient systems built around hydrophilic matrix release, tablet binding, lubrication, glidancy, film coating, and color protection.
Likely functional excipient categories
| Excipient function |
Common candidates |
Commercial purpose |
| Release-controlling matrix |
Hypromellose, hydroxypropyl cellulose, other hydrophilic polymers |
Controls guaifenesin diffusion and tablet erosion |
| Diluent |
Microcrystalline cellulose, lactose, starch, dibasic calcium phosphate |
Provides tablet mass and improves compression |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Improves granule and tablet strength |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Controls breakup of non-matrix portions |
| Lubricant |
Magnesium stearate, stearic acid |
Reduces sticking and ejection force |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Protects the tablet and improves appearance |
| Opacifier or colorant |
Titanium dioxide or approved colorants |
Supports brand differentiation and dose identification |
The key design issue is that extended-release guaifenesin tablets must balance high drug loading with adequate mechanical strength. A 600 mg or 1,200 mg dose leaves limited room for nonfunctional excipients. Excessive polymer content can produce an oversized tablet, while insufficient matrix former can cause dose dumping or release that is too rapid.
How does the excipient system control guaifenesin release?
A hydrophilic matrix is the most commercially practical strategy for high-dose guaifenesin extended-release tablets. After ingestion, the polymer hydrates and forms a gel layer. Guaifenesin then leaves the matrix through diffusion and gradual erosion.
Critical formulation variables include:
- Polymer viscosity grade.
- Polymer concentration.
- Particle-size distribution of guaifenesin.
- Granulation endpoint and moisture content.
- Compression force and tablet porosity.
- Coating weight.
- Dissolution method and acceptance criteria.
A formulation developer can tune release without changing the active ingredient by adjusting polymer grade, polymer ratio, granulation method, compression force, and tablet geometry. That creates formulation differentiation even where the product remains within the same OTC monograph framework.
Key quality attributes
The relevant critical quality attributes are:
- Assay and content uniformity.
- Extended-release dissolution profile.
- Tablet hardness and friability.
- Weight variation.
- Thickness and appearance.
- Moisture uptake.
- Stability under accelerated and long-term storage.
- Resistance to splitting or crushing where the label prohibits alteration.
- Packaging performance against humidity.
High-dose guaifenesin is also vulnerable to manufacturing challenges involving powder flow, segregation, sticking, and tablet capping. These issues create opportunities for direct-compression optimization, roller compaction, or wet granulation.
What commercial opportunities exist for excipient suppliers?
The most attractive commercial opportunities are not generic bulk excipients alone. They are integrated excipient systems that reduce development time and improve manufacturing consistency.
1. Ready-to-use extended-release matrix systems
Suppliers can offer pre-engineered hydrophilic matrix platforms using hypromellose, hydroxypropyl cellulose, or polymer blends. A co-processed system can simplify scale-up and reduce the number of formulation variables.
Value proposition:
- Faster formulation screening.
- More consistent dissolution.
- Lower development risk.
- Reduced dependence on a single polymer grade.
- Easier transfer between contract manufacturers.
2. High-load direct-compression platforms
Guaifenesin products benefit from excipients designed for high-dose direct compression. A suitable platform would combine:
- High compactibility.
- Low lubricant sensitivity.
- Good flow.
- Low segregation tendency.
- Controlled porosity.
- Acceptable tablet size.
Microcrystalline cellulose and co-processed cellulose-based systems are relevant, but the commercial opportunity depends on matching compactability with extended-release performance.
3. Taste and mouthfeel improvements
Although extended-release tablets are swallowed, large tablets can create adherence problems. Smaller tablet geometry, smoother film coating, lower tablet weight, and improved surface finish can support consumer acceptance.
Potential approaches include:
- Higher-density diluents.
- More efficient polymer matrices.
- Low-friction film coats.
- Bilayer or multilayer tablet designs.
- Alternative dosage forms for consumers with swallowing difficulty.
4. Moisture-protection systems
Retail OTC products move through warehouses, club stores, homes, and bathrooms. Moisture can alter tablet hardness, coating integrity, dissolution, and stability.
Commercial opportunities include:
- High-barrier blister packaging.
- Desiccant-equipped bottles.
- Moisture-resistant film coats.
- Low-hygroscopic excipient systems.
- Packaging and excipient combinations validated under high-humidity conditions.
Packaging changes may produce more practical shelf-life gains than reformulating the active matrix.
5. Clean-label and allergen-positioned formulations
Private-label retailers can differentiate products through excipient exclusions, provided the resulting product remains manufacturable and compliant. Potential claims or positioning may include:
- Dye-free.
- Sugar-free.
- Gluten-free, where substantiated.
- Lactose-free.
- Vegan-compatible.
- Reduced excipient count.
These changes require careful control of tablet strength, color, coating, and dissolution. Removing titanium dioxide, lactose, or certain binders can affect appearance and performance.
What formulation patents protect guaifenesin products?
Guaifenesin is an established active ingredient, and the commercial product is not dependent on new-molecule patent protection. Patent risk would instead arise from formulation, release profile, dosage form, manufacturing process, or combination claims.
Potentially relevant patent categories include:
| Patent category |
Relevance to Berkley and Jensen |
| Extended-release matrix tablet |
May cover polymer ratios, dissolution profiles, or tablet structure |
| Bilayer tablet |
Could separate immediate-release and extended-release portions |
| Abuse-deterrent or tamper-resistant dosage form |
Generally less relevant to ordinary guaifenesin |
| Effervescent or liquid formulation |
Relevant only to alternative presentations |
| Combination cough-and-cold product |
Relevant if the SKU includes dextromethorphan, pseudoephedrine, or other actives |
| Manufacturing process |
Could cover granulation, compression, coating, or release-control steps |
| Packaging |
May cover moisture-control or unit-dose configurations |
A private-label product can avoid substantial patent exposure by using a non-infringing matrix design, a different polymer architecture, or a different dissolution profile. A formulation patent does not automatically block all guaifenesin products.
What is the FDA regulatory status of Berkley and Jensen Mucus Relief?
The standard guaifenesin product is regulated as an OTC drug. Guaifenesin is addressed under FDA’s OTC monograph framework for cough, cold, allergy, bronchodilator, and antiasthmatic products.[1]
The regulatory implications are:
- The active ingredient and permitted use must conform to the applicable monograph.
- The Drug Facts label must comply with FDA labeling requirements.
- The manufacturer or private-label distributor remains responsible for quality and compliance.
- An NDA is generally not required for a monograph-compliant product.
- A reformulation may trigger new regulatory and stability work even if the active ingredient remains unchanged.
- A novel indication, nonmonograph active, or materially different delivery system may require an FDA application.
FDA’s monograph reform framework under the CARES Act replaced the former rulemaking structure with administrative orders for many OTC categories. Sponsors must assess the current monograph status rather than rely only on legacy monograph citations.[2]
What is the Orange Book status of Berkley and Jensen Mucus Relief?
Berkley and Jensen Mucus Relief is not generally expected to have an Orange Book listing comparable to an approved prescription NDA product. OTC monograph products are normally managed through the monograph and drug-listing framework rather than Orange Book patents.
The practical result is:
- No conventional Orange Book patent-certification strategy for the ordinary monograph product.
- No standard Paragraph IV litigation pathway tied to a listed NDA.
- Patent disputes would more likely involve privately asserted formulation or process patents.
- Competitive entry is primarily controlled by FDA compliance, manufacturing capability, trademark rights, retailer access, and supply economics.
When does Berkley and Jensen Mucus Relief lose exclusivity?
Berkley and Jensen Mucus Relief does not have meaningful molecule-level exclusivity. Guaifenesin has long been available in the OTC market, and competing manufacturers can market compliant guaifenesin products.
Its commercial exclusivity is based on private-label branding and retail distribution rather than a protected active ingredient. Entry can occur through:
- Competing national brands.
- Other retailer private labels.
- Store-brand contract manufacturers.
- Online OTC sellers.
- Combination products with overlapping expectorant claims.
The private-label advantage is strongest where BJ’s can maintain a price gap, reliable availability, acceptable tablet performance, and recognizable packaging.
Which companies compete with Berkley and Jensen Mucus Relief?
The principal competitive groups are:
| Competitor group |
Examples |
Competitive basis |
| Branded guaifenesin |
Reckitt’s Mucinex portfolio |
Brand recognition and product breadth |
| Retail private labels |
Store-brand expectorant products |
Lower price and retailer placement |
| Generic manufacturers |
Perrigo, ANI Pharmaceuticals, pharmaceutical contract manufacturers, and other OTC suppliers |
Cost and regulatory execution |
| Combination-product suppliers |
Manufacturers of cough, cold, and congestion products |
Multi-symptom convenience |
| E-commerce sellers |
Marketplace and direct-to-consumer brands |
Search visibility and price competition |
Contract manufacturing capacity is a major commercial variable. A supplier that can produce high-dose extended-release tablets with consistent dissolution and low defect rates can compete for multiple retailer brands using a common platform.
How strong is the patent estate for Berkley and Jensen Mucus Relief?
The patent estate is likely weak at the product level because:
- Guaifenesin is an established active ingredient.
- The product is positioned within an OTC monograph category.
- The brand is private label.
- No known NDA-based Orange Book exclusivity is apparent for the standard product.
- Competitive products can use different excipient systems and manufacturing processes.
The main residual risks are third-party patents covering a specific extended-release architecture, coating system, manufacturing process, or combination product. Freedom-to-operate analysis should focus on active U.S. patents with claims directed to guaifenesin modified release, high-dose tablets, polymer matrices, and relevant manufacturing methods.
What generic launch risks exist for this product?
Generic or private-label launch risk is moderate from a regulatory perspective and low from a molecule-patent perspective. The principal risks are operational.
| Risk |
Impact |
| Dissolution failure |
Can prevent release or trigger reformulation |
| Tablet size |
Can reduce consumer acceptance |
| High-dose compression defects |
Can increase scrap and recalls |
| Polymer variability |
Can shift the release profile |
| Moisture sensitivity |
Can reduce shelf life |
| Retailer price pressure |
Can compress supplier margins |
| Contract manufacturing concentration |
Can create supply interruption |
| Label or monograph changes |
Can require artwork and regulatory updates |
| Patent claim overlap |
Can create litigation or redesign costs |
A successful challenger would usually compete through a non-infringing formulation with equivalent labeled use, dependable supply, and a lower landed cost.
How can excipient suppliers capture value?
The highest-value strategy is to sell performance and regulatory support rather than individual ingredients. A supplier package could include:
- Extended-release matrix screening.
- High-load compression data.
- Comparative dissolution profiles.
- Excipient compatibility studies.
- Scale-up guidance.
- Stability support.
- Alternative polymer grades.
- Moisture-control recommendations.
- Documentation for quality and regulatory review.
A differentiated excipient platform should demonstrate performance in 600 mg and 1,200 mg guaifenesin tablet prototypes, including dissolution robustness across manufacturing sites and normal process variation.
Key Takeaways
- Berkley and Jensen Mucus Relief is a private-label OTC guaifenesin product, generally associated with extended-release tablets.
- Its commercial protection comes from BJ’s retail distribution and pricing, not molecule exclusivity.
- The central formulation challenge is high-dose guaifenesin release control combined with acceptable tablet size and mechanical strength.
- Hydrophilic matrix polymers, high-load compression excipients, film coatings, and moisture-control systems offer the strongest commercial opportunities.
- Orange Book and Paragraph IV issues are unlikely to be central for the standard monograph product.
- Patent risk is concentrated in formulation architecture, manufacturing processes, and any combination-product SKU.
- Excipient suppliers can create the most value through ready-to-use extended-release platforms supported by dissolution, scale-up, and stability data.
FAQs
Is Berkley and Jensen Mucus Relief the same as Mucinex?
It is generally a store-brand guaifenesin alternative. The active ingredient and labeled expectorant purpose may be comparable, but the excipient system, manufacturer, tablet design, packaging, and commercial terms can differ.
Can a manufacturer reformulate the excipients without changing guaifenesin?
Yes, provided the revised product remains compliant with the applicable FDA requirements, maintains product quality, and meets labeled performance requirements. A reformulation still requires development, stability, manufacturing validation, and regulatory review.
What excipient is most important for extended-release guaifenesin?
The release-controlling polymer system is usually the most important excipient component. Polymer viscosity, concentration, particle size, and distribution throughout the matrix can materially change dissolution.
Are guaifenesin tablets difficult to manufacture?
High-dose tablets can be challenging because the active consumes much of the tablet mass. Flow, segregation, capping, sticking, compression force, and dissolution control require close process management.
Is there a major biosimilar risk for Berkley and Jensen Mucus Relief?
No. Guaifenesin is a small-molecule OTC active, not a biologic. Biosimilar regulation does not apply. Competitive risk comes from generic, private-label, branded, and combination OTC products.
References
-
U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
-
U.S. Food and Drug Administration. (2020). Over-the-counter monograph reform in the Coronavirus Aid, Relief, and Economic Security Act. FDA.
-
U.S. Food and Drug Administration. (2024). Drug facts label requirements for over-the-counter products. FDA.
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
